معرفی
Gary Richardson is an Adjunct Clinical Professor in the Faculty of Medicine at Monash University, affiliated with the Alfred Hospital and the Victorian Heart Institute. He is a leading medical oncologist and clinical researcher based at Cabrini Health, where he serves as Director of the Szalmuk Family Department of Medical Oncology and Director of the Cabrini Institute, overseeing all research and education activities. He actively contributes to national and international oncology initiatives and is accepting PhD students through Monash University.
- Adjunct Clinical Professor, Faculty of Medicine, Monash University
- Director, Szalmuk Family Department of Medical Oncology, Cabrini Health
- Director, Cabrini Institute for Research and Education
- Alfred Hospital, Victorian Heart Institute
His research focuses on advancing cancer treatment through clinical trials, with expertise in breast, ovarian, lung, and colorectal cancers. He has participated in over 300 clinical trials and established major research institutes, including the Monash Oncology Research Institute and the Cabrini Institute. His work spans drug discovery, cancer immunotherapy, biomarkers, organoids, patient-derived models, and patient-reported outcome measures. He is a pioneer in developing Phase I trials and novel compounds for cancer therapy.
Recent publications highlight his contributions to ovarian cancer targeted therapies, lung cancer treatment quality indicators, and psycho-oncology in breast cancer survivors. His work emphasizes data-driven knowledge discovery and translational applications in clinical settings.
- Member, American Society of Clinical Oncology
- Member, Clinical Oncology Society of Australia
- Member, International Association for the Study of Lung Cancer
- Executive Member, Victorian Co-operative Oncology Group
- Former Chairman, Medical Oncology Group of Australia
- Immediate Past-President, Private Cancer Physicians of Australia
Dr. Richardson has raised over $15 million for oncology research and $2 million for men’s health initiatives. He founded Foundation 49: Men’s Health, contributing to the National Male Health Policy. He mentors future researchers and leads a robust portfolio of active grants and clinical trials, particularly in solid tumors and hematological malignancies. His leadership in policy and clinical trial design continues to shape cancer care standards in Australia.
He leads major research teams at Cabrini and Monash, directing the Phase I trial program and the electronic Patient Reported Outcomes Measurement system. His labs utilize patient-derived models and biomarker-driven approaches to personalize cancer therapy.
